Mucavex (Bromhexine Hydrochloride)

Bromhexine stimulates the production of serous mucus while breaking down the molecular bonds that make mucus thick and sticky. This dual action reduces viscosity, enhances ciliary movement, and promotes the expectoration of sputum, thereby improving airway clearance.

The dosage of Mucavex is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and renal function. The prescriber will specify the exact amount and frequency appropriate for each individual case.

Safety data for bromhexine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The most common alternative is N‑acetylcysteine, which also reduces mucus viscosity but works primarily by breaking disulfide bonds in mucin. Bromhexine, in contrast, increases serous mucus secretion and enhances ciliary activity. Clinical choice often depends on patient tolerance, specific indication and physician preference.

Mucavex should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Mucavex is taken orally, usually with a glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal discomfort. The exact administration schedule is set by the prescribing clinician.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, significant liver enzyme elevations, neutropenia, eosinophilia, and bronchospasm. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, rash, or swelling.

Mucavex is contraindicated in individuals with known hypersensitivity to bromhexine or any of its excipients. It should also be avoided in patients with severe uncontrolled asthma due to the risk of bronchospasm, and in those with severe renal impairment unless dosage adjustment is advised by a physician.